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Introduction: The aim of the present study was to evaluate the efficacy and the response in patients with mild to moderate acne of a clindamycin 
phosphate-zinc acetate topical therapy in comparison with clindamycin phosphate-zinc acetate plus adapalene. 
Methods: Patients with mild to moderate acne were randomized into two groups and treated, respectively, with a gel containing 1 % clindamycin 
phosphate-0.5% zinc acetate (2 applications/day for 12 weeks) or with the same gel (1 application/day for 12 weeks) plus a gel containing 0.1% 
adapalene (1 application/day for 12 weeks). No other topical or systemic drugs were allowed, except for a detergent and a sunscreen. 
Acne severity and treatment efficacy were evaluated by means of the Global Acne Grading System (GAGS). 
Results: At the end of the study, 63 patients were considered evaluable (29 patients in the group treated with clindamycin-zinc and 34 in the group 
treated with clindamycin-zinc and adapalene).Significant clinical improvement (£50% from baseline) was observed in 12/29 patients (41.4%) in the group 
treated with clindamycin-zinc and in 22/34 patients (64.7%) in the group treated with clindamycin-zinc and adapalene (p< 0.05). 
Irritant contact dermatitis was observed in 12 patients (3 in the group treated with clindamycin-zinc and 9 in the group treated with clindamycin-zinc and 
adapalene); in the latter group, two patients stopped the treatment. 
Conclusions: On the basis of the results of this study, which is the first one on the activity and tolerability of the association clindamycin-zinc, the latter 
association is less effective than the association clindamycin-zinc and adapalene. 
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